M. Victoria Purvis Miles

M. Victoria Purvis Miles

Auto-generated profile, based on publicly available information

M. Victoria Purvis Miles

Louisiana State University Health and Sciences Center , New Orleans, LA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
MMM. Victoria P. Miles
M. Victoria P. Miles
RHR. Chace Hicks
R. Chace Hicks
HPHunter Parmer
Hunter Parmer
CBChadwick Brown
Chadwick Brown
AEAbigail Bs Edwards
Abigail Bs Edwards
RMRobert Md Maxwell
Robert Md Maxwell
BACKGROUND: Platelet dysfunction is known to occur in patients with traumatic brain injury (TBI), and the correction of platelet dysfunction may prevent hemorrhagic progression in TBI. Thromboelastography with platelet mapping (TEG-PM; Haemonetics) evaluates the degree of platelet function inhibition through the adenosine diphosphate (ADP) and arachidonic acid (AA) pathways. We hypothesized that ADP and AA inhibition would improve with the transfusion of platelets in patients with TBI. METHODS: A retrospective review was conducted at a Level I trauma center of all patients presenting with TBI from December 2019 to December 2020. Per a practice management guideline, a platelet mapping assay was obtained on all patients with TBI upon admission. If ADP or AA was found to be inhibited (>60%), the patient was transfused 1 unit of platelets and a repeat platelet mapping assay was ordered. Demographic data, laboratory values, and outcomes were analyzed. RESULTS: Over the 13-month study period, 453 patients with TBI underwent TEG-PM with a protocol adherence rate of 66.5% resulting in a total of 147 patients who received platelets for ADP and/or AA inhibition; of those, 107 underwent repeat TEG-PM after platelets were administered. With the administration of platelets, ADP (p < 0.0001), AA (p < 0.0001), and MA (p = 0.0002) all significantly improved. Of 330 patients with TBI not taking antiplatelet medications, 50.9% showed inhibition in ADP and/or AA. If AA or ADP inhibition was noted on admission, mortality was increased (p = 0.0108). If ADP improved with platelet administration, the need for neurosurgical intervention was noted to decrease (p = 0.0182). CONCLUSION: Patients with TBI and platelet inhibition may benefit from the administration of platelets to correct platelet dysfunction. Thromboelastography with platelet mapping may be implemented in the initial workup of patients presenting with TBI to assess platelet dysfunction and provide prognostic information, which may guide treatment. LEVEL OF EVIDENCE: Therapeutic / Care Management, level III.

5 September 2018 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
PBPhillip G Brennan
Phillip G Brennan
JLJames K Landry
James K Landry
MMM Victoria P Miles
M Victoria P Miles
ALAlicia C Lintner
Alicia C Lintner
KMKaitlin A McGinn
Kaitlin A McGinn
SKSteven A Kahn
Steven A Kahn
Little has been published regarding intravenous (IV) ketamine for burn wound care in adult patients. Ketamine may serve as a safe alternative to provide conscious sedation and limit opioid administration to patients. The purpose of this study was to characterize IV ketamine use during burn wound care and establish its potential role as a safe adjunct to opioid and benzodiazepine medications. This is a retrospective review of adult patients admitted to a regional burn center who received IV ketamine for burn wound care. Patient demographics, medications, and ketamine-related side effects including hypertension and dysphoric reactions were recorded. Cardiopulmonary complications were also tracked. Thirty-six patients met inclusion criteria; 50 total cases were performed. The median patient age was 37 [IQR 28 – 55] years with a median burn size of 9.5 [IQR 4.0 – 52] %TBSA. The median ketamine dose administered was 1.2 [IQR 0.8 – 2.1] mg/kg. IV midazolam was administered in almost all cases (98%) at a median dose of 3.0 [IQR 2.0 – 5.0] mg. Opioids were administered in 13 of 50 cases (26%) at a median morphine equivalent dose of 10 [IQR 5.0 – 18] mg. In 46 cases (92%), patients denied unpleasant recall of medication. Dysphoric reactions were observed in 3 cases (6%). Ketamine-induced hypertension occurred in 3 cases (6%) and all immediately responded to IV labetalol. There were no cardiopulmonary complications. These findings suggest IV ketamine provides a safe analgesia and sedative option for burn wound care. Given these findings, IV ketamine for burn wound care warrants further study.

19 September 2019 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
ALAlicia C. Lintner
Alicia C. Lintner
PBPhillip Brennan
Phillip Brennan
MMM. Victoria P. Miles
M. Victoria P. Miles
CLClinton Leonard
Clinton Leonard
KAKaitlin M Alexander
Kaitlin M Alexander
SKSteven A Kahn
Steven A Kahn
Providing adequate analgesia during burn wound care is essential to patient-centered care. Both oral and intravenous (IV) ketamine are often used for analgesia and sedation. Ketamine may improve analgesia and decrease opioid requirements for burn wound care. Oral ketamine wafers and tablets have been used as a safe alternative internationally but are unavailable in the United States. The purpose of this study was to compare opioid usage and patient satisfaction scores in patients with and without the use of oral injectable ketamine for burn wound care, with each patient serving as their own control. Ketamine, opioid, and benzodiazepine dosages recorded during dressing changes were compared to dressing changes without ketamine use that occurred before and after ketamine-associated sessions in each patient. Fourteen patients received oral ketamine at a median (interquartile range [IQR]) dose of 2.5 (2.2-2.7) mg/kg. Ketamine use significantly decreased opioid requirements when compared to wound care sessions that did not use ketamine both before (50 [IQR: 30-75] mg vs 75 [IQR: 46–91] mg median IV morphine equivalents, P = .0097) and after (50 [IQR: 30-75] mg vs 63 [IQR: 50-96] mg median IV morphine equivalents, P = .0042) the ketamine-associated sessions. One patient experienced hallucinations, and no adverse events were observed. Hence, oral administration of injectable ketamine was associated with a decrease in opioid requirements during dressing changes. Additionally, ketamine use improved patient satisfaction (P = .0034). Preliminary data suggest this promising analgesia method is safe and effective for burn wound care.

28 April 2022 in Journal of Surgical Education
Verified
Journal Article
Closed access
VMVictoria P. Miles
Victoria P. Miles
RSRebecca W. Schroll
Rebecca W. Schroll
JBJennifer S. Beaty
Jennifer S. Beaty

8 November 2021 in The American Surgeon™
Verified
Journal Article
Closed access
PDF file
NFNadia M. Froehling
Nadia M. Froehling
JMJames A. Martin
James A. Martin
MMM. Victoria P. Miles
M. Victoria P. Miles
AWAndrew W. Wilson
Andrew W. Wilson
BBBrynn Byers
Brynn Byers
LSLisa A. Smith
Lisa A. Smith
Surgical correction of pectus excavatum by Nuss procedure, commonly referred to as minimally invasive repair of pectus excavatum (MIRPE), often results in significant postoperative pain. This study investigated whether adding intraoperative methadone would reduce the postoperative opioid requirement during admission for patients undergoing MIRPE. A retrospective cohort chart review was conducted for 40 MIRPE patients between 2018 and 2020. Patients were stratified into 2 groups: those who received multimodal anesthesia (MM, n = 20) and those who received multimodal anesthesia with the addition of intraoperative methadone (MM + M, n = 20). Data collected included total opioid consumption during hospital stay (morphine milligram equivalents [MMEs]), hospital length of stay (LOS), pain scores, time to ambulation, and time to tolerating solid food. Addition of intraoperative methadone for patients undergoing MIRPE significantly reduced postoperative opioid requirements (MME/kg) during admission (P = .007). On average, patients in the MM group received 1.61 ± .55 MME/kg while patients in the MM + M group received 1.16 ± .44 MME/kg. Hospital opioid (non-methadone) total was also significantly reduced between the MM (1.87 ± .54) and MM + M group (1.37 ± .46), P = .003. There was no significant difference in hospital opioid total MME/kg administered between the groups. There were no significant differences observed in hospital LOS, pain scores, time to ambulation, or time to toleration of solid food. Incorporating intraoperative methadone for patients undergoing MIRPE reduced postoperative opioid requirements and hospital opioid (non-methadone) totals without a significant change in pain scores. Patients undergoing the Nuss procedure may benefit from the administration of intraoperative methadone.

26 September 2023 in The American Journal of Surgery
Verified
Journal Article
Closed access
LFL. Favors
L. Favors
KHK. Harrell
K. Harrell
VMV. Miles
V. Miles
RHR.C. Hicks
R.C. Hicks
MRM. Rippy
M. Rippy
RMR. Maxwell
R. Maxwell